Pharmacogenomics and bioinformatics: PharmGKB.
The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted research from candidate gene pharmacogenetics to phenotype-based pharmacogenomics with a consequent explosion of data. PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways. Going forward, the challenges are to provide the tools and knowledge to plan and interpret genome-wide pharmacogenomics studies, predict gene-drug relationships based on shared mechanisms and support data-sharing consortia investigating clinical applications of pharmacogenomics.
Thorn
Caroline F
CF
Department of Genetics, Stanford University Medical Center, Stanford, CA 94305-5120, USA.
Klein
Teri E
TE
Altman
Russ B
RB
D019295:Computational Biology / Q000379:methods* / Q000639:trends; D016208:Databases, Factual; D004194:Disease / Q000235:genetics; D004358:Drug Therapy; D020407:Internet; D051188:Knowledge Bases; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends
D004364:Pharmaceutical Preparations